- Sections
- A - Nécessités courantes de la vie
- A61K - Préparations à usage médical, dentaire ou pour la toilette
- A61K 38/20 - Interleukines
Détention brevets de la classe A61K 38/20
Brevets de cette classe: 4873
Historique des publications depuis 10 ans
|
231
|
232
|
279
|
373
|
352
|
426
|
399
|
429
|
386
|
298
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Iovance Biotherapeutics, Inc. | 345 |
93 |
| The Regents of the University of California | 20211 |
60 |
| Massachusetts Institute of Technology | 10131 |
56 |
| University of Pittsburgh - Of the Commonwealth System of Higher Education | 3204 |
51 |
| Altor BioScience, LLC | 76 |
47 |
| The Board of Trustees of the Leland Stanford Junior University | 6507 |
46 |
| Inserm (institut National de La Sante et de La Recherche Medicale) | 3370 |
41 |
| Immunitybio, Inc. | 454 |
40 |
| Novartis AG | 10674 |
39 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2895 |
39 |
| Memorial Sloan-Kettering Cancer Center | 1970 |
36 |
| Genentech, Inc. | 4017 |
34 |
| Nektar Therapeutics | 437 |
34 |
| Regeneron Pharmaceuticals, Inc. | 4394 |
33 |
| Bristol-myers Squibb Company | 4847 |
32 |
| The Trustees of the University of Pennsylvania | 4377 |
32 |
| Genexine, Inc. | 109 |
31 |
| Xencor, Inc. | 395 |
31 |
| Dana-Farber Cancer Institute, Inc. | 2613 |
30 |
| Philogen S.p.A. | 126 |
28 |
| Autres propriétaires | 4040 |